Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • Dairy Nutritional’s infant formula project is expected to arrive in Australia in late July 2019 – two months ahead of schedule
  • The Board is satisfied with due diligence investigations relating to the purchase of the plant

The Board at Australian Dairy Nutritionals Group has announced it has completed and is satisfied with investigations relating to the purchase of the infant formula plant.

On April 4 Dairy Nutritionals announced the purchase of an existing and offshore infant formula plant with initial capacity to produce between 400,000 and 600,000 tins of infant formula per year.

This will allow Dairy Nutritionals to produce its own range of organic infant formulas with milk sourced from its own farm.

The plant will be used to produce traditional skim and whole milk powders with the ability to produce niche powders such as sheep, goat and camel which are currently in high demand. Its cheese plant will also be used to produce speciality ingredients such as organic whey.

It was also announced prior to delivery that the plant will require dismantling, relocation and reassembly in a special purpose building. The plant previously belonged to a Chinese producer and exporter however they outgrew the production capacity.

The total cost of the plant is $5 million dollars with expected arrival to Australia in September 2019.

Dairy Nutritionals announced today that decommissioning and dismantling of the plant commenced this week with it expected to arrive in Australia in late July 2019. Dairy expects the purchase of the plant to be completed in August 2019 just after the expected arrival.

Once completed this will propel Dairy Nutritionals into becoming one of Australia’s first vertically integrated manufacturers of organic infant formula.

AHF by the numbers
More From The Market Herald

" Orbital Corporation (ASX:OEC) to assist Skyways with US Navy platform

Orbital Corporation (OEC) has signed Texas-based cargo transport company Skyways as its newest customer.
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.